Coriolis Pharma Opens New Laboratory at Spark Life Science Campus in Morrisville, North Carolina

New site in North Carolina strengthens Coriolis’ global presence and brings core services closer to the US market

Martinsried-Munich, Germany, July 22, 2025 – Coriolis Pharma, a globally operating Contract Research and Development Organization (CRDO) and a leader in formulation research and development for biopharmaceuticals, today announced its intention to invest $10 million in establishing a state-of-the-art research laboratory and creating 50 jobs at Spark LS, an innovative life science campus in Morrisville, North Carolina.

The new laboratory will encompass approximately 13,000 square feet and is scheduled to commence operations in the first quarter of 2026. As a strategic anchor for Coriolis Pharma’s North American expansion, the facility will initially deliver core services such as particle identification, followed by formulation development and lyophilization. These offerings will be seamlessly integrated with the company’s global scientific and operational network, ensuring continuity and excellence through close collaboration with its headquarters in Germany. The site is designed to support future innovation, including the adoption of advanced digital and in-silico technologies, reinforcing Coriolis Pharma’s vision to accelerate and de-risk biopharmaceutical development.

“The investment in a new lab in Morrisville is a significant milestone for Coriolis. With our future presence in North Carolina, we will be able to serve our North American clients even better, offering our core services quickly and efficiently on site,” said Silvia Steyrer-Gruber, Chief Executive Officer of Coriolis Pharma. “The decisive factor in our choice of location was the strong scientific fit with the North Carolina ecosystem, a global biotechnology center of excellence. The innovative environment, proximity to numerous life science companies and excellent infrastructure around Morrisville, reinforced our decision”.

“We are thrilled to welcome Coriolis Pharma to Spark, marking a significant milestone for our campus,” said Jeff Sheehan, Managing Partner at Trinity Capital, Spark’s developer. “Coriolis Pharma’s decision to establish their U.S. headquarters and first U.S. lab here at Spark is a testament to the innovative environment we’re cultivating and the immense potential within the region’s burgeoning biotech sector. We look forward to supporting their groundbreaking work and are excited about the collaborative opportunities this brings to our campus.”

Spark LS is the region’s largest mixed-use life science and innovation campus, featuring world-class amenities, multi-functional spaces across 1.5 million square feet of cutting-edge laboratory and biomanufacturing space. The approximately 108-acre campus is located close to the Research Triangle Park in the Raleigh-Durham MSA. Offering access to restaurants, conference and meeting rooms, fitness facilities, and expansive green areas, it provides an ideal environment for research, development, and collaboration.

Coriolis Pharma brings a unique combination of cross-modality formulation expertise, scientific depth, and advanced analytical capabilities to the pharmaceutical and biotech industry in North Carolina. The investment in the new laboratory underscores the company’s strategic commitment to expanding its global innovation footprint and accelerating digital transformation in drug development. Guided by a clear mission to convert cutting-edge biomolecules into life-saving therapies, Coriolis Pharma continues to set new standards in formulation science and biopharmaceutical advancement.

In the coming months, Coriolis Pharma will advance the build-out of the North Carolina laboratory and begin hiring its first new employees.

End of Press Release